Osteoarthritis and Bone Disorders News

Patients with autoimmune rheumatic diseases who are undergoing elective hip or knee arthroplasty should maintain their usual doses of methotrexate, leflunomide, hydroxychloroquine, sulfasalazine and apremilast , according to new guidelines.

Women with polycystic ovary syndrome were more likely to have myriad medical conditions, use medications more often and report poorer health than women who did not have the disorder, according to a population-based Finnish study.

In a cohort of women, NSAID use significantly decreased the efficacy of the bisphosphonate clodronate for preventing bone loss and fractures, according to findings from a post hoc analysis.

There is a “direct correlation” between microscopic particles found in air pollution and increased incidence of osteoporosis and autoimmune disease in a cohort of individuals in Italy, according to a presenter at the EULAR 2022 Congress.

Patients with knee osteoarthritis receiving antihistamines demonstrate less structural disease progression, compared with those who did not take antihistamines, over 2 years, according to data presented at the EULAR 2022 Congress.

DESTIN, Fla. — Cell senescence may represent the “most exciting” development in the potential treatment of osteoporosis, according to Michael R. McClung, MD, of Australian Catholic University and the Oregon Osteoporosis Center.

In honor of Osteoporosis Awareness Month in May, advocacy organizations used social media to spread the word about the disease, including tips for patients on how to better manage their disease.

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.

Among the many unanswered questions about calcium pyrophosphate deposition — formerly called “pseudogout” — perhaps the most important is whether it causes osteoarthritis, a speaker said at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — Understanding when to switch from one class of drugs to another is critical to maintaining bone health and preventing fractures in osteoporosis, according to data presented at the Congress of Clinical Rheumatology East.